Dexxon, SoftBank and Sumitomo Dainippon-backed medical company builder Roivant Sciences will get a public listing through the transaction.
Roivant Sciences, the US-based biopharmaceutical company backed by telecommunications and internet group SoftBank and pharmaceutical firms Sumitomo Dainippon Pharma and Dexxon, agreed a reverse merger yesterday at a combined $7.3bn valuation.
The deal will take place with Montes Archimedes Acquisition Corp, a special purpose acquisition company sponsored by healthcare investment firm Patient Square Capital, which floated on the Nasdaq Capital Market in a $400m initial public offering in October 2020.
Sumitomo Dainippon, SoftBank subsidiary SB Management and data analytics…
